Drug Profile
Research programme: pineapple protease chemotherapy - Medical Marketing International
Alternative Names: Pineapple proteaseLatest Information Update: 04 May 2010
Price :
$50
*
At a glance
- Originator Provalis
- Developer Medical Marketing International Group
- Class Peptides
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2009 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 16 Aug 2007 Preclinical development is ongoing
- 20 Nov 2001 Provalis has licensed its pineapple protease research programme to Medical Marketing International